Humanigen Inc (fka HGENQ)

[Fress]

This stock at these levels is a great investment.


I see new 52 week highs coming.


Developing our immunology and immuno-oncology portfolio of monoclonal antibodies. chimeric antigen receptor T-cell.


insiders & Institution almost 75% of all the shares.


only 50 million shares & 100 million in cash.


BARDA & NIH supporting phase 3 clinical trial for CV-19.

Positive Interim Phase 3 Data of Lenzilumab in COVID-19
• Interim analysis conducted on the first 165 patients
• Estimated 37% more recoveries observed with lenzilumab vs current standard of care
• Lenzilumab is tracking to a result that is significantly above and beyond steroids and/or remdesivir
• DSMB recommendation to expand the study
• Phase 3 trial is significantly de-risked by this data and current study plan
• With the current study plan, the trial is 90% powered and has a high probability of success
• Total of 515 patients to be enrolled in phase 3 study
• EUA filing expected in Q1 2021

https://www.humanigen.com/about-humanigen


https://www.humanigen.com/pipeline

HGEN Dec 2020 Biz presentation.
https://9e234b13-0cc4-4c74-b924-d7874342289e.filesusr.com/ugd/6ca631_f09ac3ab726d483b960e06c1efb6ec95.pdf





$HGEN